Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Synergistic Anticancer Activities of Natural Substances in Human Hepatocellular Carcinoma.

Kojima-Yuasa A, Huang X, Matsui-Yuasa I.

Diseases. 2015 Oct 22;3(4):260-281. doi: 10.3390/diseases3040260. Review.

2.

The synergistic effect of 1'-acetoxychavicol acetate and sodium butyrate on the death of human hepatocellular carcinoma cells.

Kato R, Matsui-Yuasa I, Azuma H, Kojima-Yuasa A.

Chem Biol Interact. 2014 Apr 5;212:1-10. doi: 10.1016/j.cbi.2014.01.010. Epub 2014 Jan 28.

PMID:
24480522
4.

Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells.

Du Q, Hu B, An HM, Shen KP, Xu L, Deng S, Wei MM.

Oncol Rep. 2013 May;29(5):1851-8. doi: 10.3892/or.2013.2310. Epub 2013 Feb 27.

PMID:
23446753
5.

Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.

Lange M, Abhari BA, Hinrichs TM, Fulda S, Liese J.

Biochem Pharmacol. 2016 Oct 15;118:9-17. doi: 10.1016/j.bcp.2016.08.011. Epub 2016 Aug 17.

PMID:
27544320
6.

Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.

Hu Z, Lv G, Li Y, Li E, Li H, Zhou Q, Yang B, Cao W.

J Exp Clin Cancer Res. 2016 Apr 22;35:71. doi: 10.1186/s13046-016-0349-4.

7.

A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.

Yamashita M, Wada H, Eguchi H, Ogawa H, Yamada D, Noda T, Asaoka T, Kawamoto K, Gotoh K, Umeshita K, Doki Y, Mori M.

Int J Oncol. 2016 Jul;49(1):89-98. doi: 10.3892/ijo.2016.3496. Epub 2016 Apr 25.

8.

5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.

Hu XY, Liang JY, Guo XJ, Liu L, Guo YB.

Clin Exp Pharmacol Physiol. 2015 Feb;42(2):146-53. doi: 10.1111/1440-1681.12333.

PMID:
25363523
9.

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells.

Wang D, Meng G, Zheng M, Zhang Y, Chen A, Wu J, Wei J.

PLoS One. 2016 Nov 11;11(11):e0166423. doi: 10.1371/journal.pone.0166423. eCollection 2016.

10.

Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.

Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, Wang Y.

J Ethnopharmacol. 2013 Oct 7;149(3):601-12. doi: 10.1016/j.jep.2013.07.030. Epub 2013 Aug 1. Review.

PMID:
23916858
11.

Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.

Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K, Yoshii J, Namisaki T, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H.

Oncol Rep. 2007 Feb;17(2):441-6.

PMID:
17203185
12.

Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.

Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F.

Mol Cancer Ther. 2012 Oct;11(10):2284-93. doi: 10.1158/1535-7163.MCT-12-0093. Epub 2012 Aug 17.

13.

The role of ROS-induced autophagy in hepatocellular carcinoma.

Yuan X, Wang B, Yang L, Zhang Y.

Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):306-312. doi: 10.1016/j.clinre.2018.01.005. Epub 2018 Mar 12.

PMID:
29544680
14.

Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.

Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, Zhang M, Xing D.

Oncol Lett. 2017 Mar;13(3):1509-1517. doi: 10.3892/ol.2017.5602. Epub 2017 Jan 17.

15.

Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.

Chen G, Wang K, Yang BY, Tang B, Chen JX, Hua ZC.

Int J Oncol. 2012 Jan;40(1):139-47. doi: 10.3892/ijo.2011.1210. Epub 2011 Sep 22.

PMID:
21947421
16.

3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.

Lee M, Jo A, Lee S, Kim JB, Chang Y, Nam JY, Cho H, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.

PLoS One. 2017 Mar 31;12(3):e0174271. doi: 10.1371/journal.pone.0174271. eCollection 2017.

17.

Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.

El-Shemi AG, Ashshi AM, Na Y, Li Y, Basalamah M, Al-Allaf FA, Oh E, Jung BK, Yun CO.

J Exp Clin Cancer Res. 2016 May 6;35:74. doi: 10.1186/s13046-016-0353-8. Erratum in: J Exp Clin Cancer Res. 2016;35(1):96.

18.

Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.

Lim SC, Choi JE, Kang HS, Han SI.

Int J Cancer. 2010 Apr 1;126(7):1582-95. doi: 10.1002/ijc.24853. Erratum in: Int J Cancer. 2010 Jul 15;127(2). doi: 10.1002/ijc.25347. Si, Han [corrected to Han, Song Iy].

19.

Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.

Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu Y, Lu J.

PLoS One. 2012;7(12):e51461. doi: 10.1371/journal.pone.0051461. Epub 2012 Dec 11.

20.

Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.

Mao CY, Hua HJ, Chen P, Yu DC, Cao J, Teng LS.

Hepatobiliary Pancreat Dis Int. 2009 Jun;8(3):282-7.

Supplemental Content

Support Center